ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ETON
OCUL (24) INVA (65) PCRX (65) TYRA (30) ⌘ Pro Terminal →

Eton Pharmaceuticals Inc. (ETON) — RQD Stock Rating Cockpit

$50.81 -2.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $50.47

Eton Pharmaceuticals Inc. (ETON) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $1.49B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ETON Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ETON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Eton Pharmaceuticals Inc. (NASDAQ: ETON) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $50.81 (-2.63% 1D, market cap $1.49B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, ETON ranks #191 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ETON compare to OCUL and INVA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ETON carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 53.5%, and ROIC of -0.9%. By comparison, OCUL (Ocular Therapeutix Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.53B) and INVA (Innoviva Inc.) posts a C grade (65/100 RQD, P/E N/A, ROIC 14.7%, cap $1.53B). Among the 5-stock peer group, ETON leads on earnings multiple (N/A) while INVA leads on capital efficiency (14.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ETON?
▼

Per ETON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001710340), Eton Pharmaceuticals Inc. generated $80.0M in revenue (+104.9% YoY), -$4.6M in net income, and $10.2M in free cash flow against $92.1M in total assets and $21.8M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $50.47 (-0.66%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 12.7% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510057
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D · Rk B-
Cash (13)Whales (10)SEC (16)Macro (12)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-0.5% Base Target
$70 Bull$51 Base$39 Bear
📬 FREE ETON RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ETON)Realized 20D OHLCV Swing Band: ±9.6%
Deterministic 5-Pillar Attribution (57/100 Composite)
🔍 WHY ETON SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (28% of score)

Altman Z-Score 13.37 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 12.7% FCF Margin ($10.2M FCF) & 53.5% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)

Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
65
Grade C+$53.33-5.9% Next Q
Q2 (-2Q)
62
Grade C+$50.19+1.9% Next Q
Q3 (-1Q)
60
Grade C$51.16-0.7% Next Q
Current
57
Grade D+$50.81-0.2% Hist 90D α
Trajectory: C+ (65) → D+ (57)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ETON Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, ETON faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Dilution Drag (+1.64% YoY Shares) — any gross margin slip below 51.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($55.56) or 200D SMA ($36.08) invalidates the momentum regime and cuts Target Base ($50.58) toward Bear Floor ($39.45).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ETON• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ETON Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 57%NO 43%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
47.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
13.37>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE70% OF RANGE
L: $14$50.81H: $66
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (53.5% gross margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

Quant Analyst Panel Split (Battleground) on ETON

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (65)

-0.9% ROIC with 53.5% gross margin and 0.66% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 13.37 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (47)

16/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like ETON
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ETON)

  • ✓Walkthrough of ETON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ETON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +68.47%🛡️ HOLDING TREND SUPPORT
2026-11-03O $53.67H $53.67L $50.81C $50.81VOL 336.2K
RES: $71.64SUP: $50.49SMA50: $55.56SMA200: $36.08
$69.73$55.80$41.86$27.92$13.98RES $71.64SUP $50.49$50.812026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ETON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ETON Butterfly Map → + Track ETON →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +104.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ETON today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ETON. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ETON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ETON)

Health Care Rank #191 of 1015 ⚔️ OCUL vs ETON Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ETON vs. OCUL, INVA, PCRX, TYRA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Eton Pharmaceuticals Inc. (ETON) ranks #191 by composite RQD confidence (57/100, grade D+) and #302 by equity capitalization ($1.49B). Within this direct 5-issuer industry benchmark cohort, ETON leads on earnings valuation at N/A trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with ETON at 57/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ETON ACTIVE
Eton Pharmaceuticals Inc.
D+ 57/100 — 53.5% -0.9% -2.63% $1.49B Benchmark Subject
OCUL
Ocular Therapeutix Inc.
E 24/100 — 87.3% -35.0% -3.44% $1.53B /ocul-vs-eton →
INVA
Innoviva Inc.
C 65/100 — 74.8% 14.7% -0.94% $1.53B /inva-vs-eton →
PCRX
Pacira BioSciences Inc.
C 65/100 — 79.4% 1.7% +0.03% $1.45B /pcrx-vs-eton →
TYRA
Tyra Biosciences Inc.
E 30/100 — — -35.0% +1.23% $1.45B /tyra-vs-eton →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001710340 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eton Pharmaceuticals Inc. (ETON) reported GAAP revenue of $80.0M (+104.9% vs. FY2024 revenue of $39.0M , and +152.7% cumulative change since FY2023) , GAAP net income of -$4.6M, operating cash flow of $10.5M, and free cash flow of $10.2M (+980.7% YoY). On the balance sheet, ETON closed FY2025 with $92.1M in total assets against $21.8M in total debt (Altman Z-Score: 13.37, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $80.0M -$4.6M $10.5M $10.2M $92.1M $21.8M
FY2024 (FY) 2024-12-31 $39.0M -$3.8M $969.0K $943.0K $76.1M $29.8M
FY2023 (FY) 2023-12-31 $31.6M -$936.0K $6.8M $6.8M — —

3. ETON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ETON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Eton Pharmaceuticals Inc. (NASDAQ: ETON) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $50.81 (-2.63% 1D, market cap $1.49B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, ETON ranks #191 in composite RQD confidence.

How does ETON compare to OCUL and INVA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ETON carries a Roarable D+ (57/100 RQD), trailing P/E of N/A, gross margin of 53.5%, and ROIC of -0.9%. By comparison, OCUL (Ocular Therapeutix Inc.) holds a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.53B) and INVA (Innoviva Inc.) posts a C grade (65/100 RQD, P/E N/A, ROIC 14.7%, cap $1.53B). Among the 5-stock peer group, ETON leads on earnings multiple (N/A) while INVA leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ETON?

Per ETON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001710340), Eton Pharmaceuticals Inc. generated $80.0M in revenue (+104.9% YoY), -$4.6M in net income, and $10.2M in free cash flow against $92.1M in total assets and $21.8M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ETON trading relative to its 50-day, 200-day, and 52-week technical levels?

ETON last traded at $50.81 (-2.63% on volume of 557,244 shares), positioning the stock -8.55% below its 50-day simple moving average ($55.56) and +40.83% above its 200-day simple moving average ($36.08). Across its 52-week range of $14.27 to $66.37, ETON sits at the 70.1% percentile with a 14-day RSI of 47.9 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($45.93 to $55.69).

Direct Sub-Reports: ETON RQD Cockpit ETON 12M Forecast ETON Earnings & Move ETON Dividends & DRIP ETON Insiders & 13F ETON Whale Options ETON Profit Sankey ETON News & Why
ROARABLE RATING BRIEF • RQD 57/100 (D+) ✓ SEC XBRL & RQD VERIFIED

ETON — Eton Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Eton Pharmaceuticals Inc. (ETON) earns a live Roarable RQD composite score of 57/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $50.81 (-2.63% 1D, market capitalization $1.49B).

  • Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of -0.9%, gross margin of 53.5%, operating margin of -1.1%, and free cash flow yield of 0.66%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 13.37, Piotroski F-Score of 7/9, and Debt/Equity of 0.83x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Eton Pharmaceuticals Inc. (ETON) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The company's market capitalization is $1.5B. Per the news wire, a headline references a new seizure drug license.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Eton Pharmaceuticals Inc. (ETON) reported $80.0M in annual revenue (up from $39.0M in FY2024, +104.9% YoY) and -$4.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($31.6M revenue, -$936.0K net income) through FY2025, ETON scaled operating cash flow to $10.5M and free cash flow to $10.2M, backed by $92.1M in total assets against $21.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 57/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 0.66% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $14.27 – $66.37 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -1.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ETON carries a macro regime beta of 1.00 and gross margin of 53.5%.

  • Key Question #1: Can ETON sustain or expand its -1.1% operating margin and -0.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $80.0M and free cash flow of $10.2M, how will capital allocation balance growth reinvestment against $21.8M in total debt?
  • Key Question #3: How sensitive is ETON's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ETON Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Eton Pharmaceuticals Inc. (ETON) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ETON Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ETON Bull vs. Bear Conversation Board — What's Your Call at $50.81?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ETON 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ETON:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $62.62 (+20.0%)
📌 Pinned Debate

Revenue grew from $31.6M in FY 2023 to $80.0M in FY 2025 while the balance sheet scores strongly on Altman Z of 13.37 and Piotroski F o

Long ETON at $52.18 targeting $62.62. Revenue grew from $31.6M in FY 2023 to $80.0M in FY 2025 while the balance sheet scores strongly on Altman Z of 13.37 and Piotroski F of 7/9.. Institutional whale score is 10/20 and the risk/reward vs. the $14.27 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@FadeTheHype Shorting a 10/20 institutional whale-flow stock at $52.18 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $39.13 (-25.0%)
Spot @ $52.18

ROIC is -0.9%, FCF yield is 0.66%, and the insider-conviction pillar scores only 6 of 20.

Sitting on the sidelines or leaning short ETON above $52.18. ROIC is -0.9%, FCF yield is 0.66%, and the insider-conviction pillar scores only 6 of 20.. Until Fundamental Cash Engine (13/20) and FCF yield (0.66%) inflect higher, upside is capped near $66.37.

LIVE TAPE